ACADIA Pharmaceuticals Inc. (ACAD)
NASDAQ: ACADHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ACAD stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.96B
- P/E (TTM)
- 8.07
- Forward P/E
- 15.75
- EPS (TTM)
- $2.12
- Dividend yield
- None
- 52-week range
- 15.86 – 30.96
- Day range
- 17.05 – 17.79
- Volume / Avg
- 1.90M / 2.18M
- Beta
- —
- Shares outstanding
- 172.83M
52-week range
ACAD stock today
ACADIA Pharmaceuticals (ACAD) closed at $17.11 on Nov 20, down 2.73% (-$0.48), versus the S&P 500's 3.70% decline. Shares are 44.7% below their 52-week high of $30.96, set on Aug 19, 2026 and 7.9% above the 52-week low of $15.86, near the bottom of the past year's range. ACAD is down 35.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 27.4%.
ACADIA Pharmaceuticals trades at 8.1x its trailing twelve-month earnings per share of $2.12. Its forward P/E of 15.8x is higher than the trailing multiple, which means analysts expect earnings to decline over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About ACADIA Pharmaceuticals
Company profileACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer's disease psychosis and lewy body dementia psychosis; ACP-211, which is in phase 2 clinical trial to treat major depressive disorder; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; and ACP-271, a GPR88 agonist for the treatment of tardive dyskinesia and huntington's disease and is in phase I trial.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Ms. Catherine E. Owen Adams
- Headquarters
- San Diego, CA
- Employees
- 796
- IPO year
- 1985
- Website
- acadia.com
Financial highlights
Full financialsIn fiscal 2025, ACADIA Pharmaceuticals generated $1.07 billion in revenue, up 11.9% from fiscal 2024, its 10th consecutive year of revenue growth. Net income was $391.0 million (+72.7% year over year), for a net margin of 36.5% versus a median of -34.7% in the prior 5 years. Gross margin was 91.7% (up from 91.5%) and operating margin 9.8%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $1.07B | $957.80M | $726.44M | $517.24M | $484.14M |
| Growth | +11.87% | +31.85% | +40.45% | +6.83% | +9.60% |
| Net income | $391.00M | $226.45M | $-61.29M | $-215.97M | $-167.87M |
| EPS (diluted) | $2.30 | $1.36 | $-0.37 | $-1.34 | $-1.05 |
Analyst forecast
ForecastConsensus (20 analysts)
buy
Avg. price target
$30.32+77.21%
- Strong buy 4
- Buy 10
- Hold 5
- Sell 1
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 4, 2026
- EPS actual vs est.
- $0.26 vs $0.19
- Surprise
- +36.84%
ACAD news
All ACAD news- Acadia Expands Rett Syndrome Partnership In Japan Through KYORIN AgreementNasdaqACAD, LEN.B
- Acadia Pharmaceuticals Enters Oversold Territory (ACAD)Nasdaq
- Acadia Pharmaceuticals Reports Third Quarter 2026 Financial ResultsBusiness Wire
- Viatris Gears Up to Report Q3 Earnings: Is a Beat in the Cards?NasdaqVTRS, TGTX, ACAD, IOVA
- Tarsus Names Neera Clase Commercial Chief To Expand XDEMVY Reach And Lead Pipeline PlanningNasdaqABT, ACAD, TARS, BRK.A
- Acadia Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 4, 2026Business Wire
- Will Auvelity Continue to Aid Axsome's Top-Line Growth in Q3?NasdaqAXSM, JAZZ, ACAD
- 4 CNS Drug Stocks Worth Watching This World Mental Health DayNasdaqALKS, NBIX, ACAD, AXSM
ACADIA Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| LEGNLegend Biotech Corporation ADR | 15.25 | -5.28% | $2.96B | vs ACAD |
| DYNDyne Therapeutics Inc. | 15.50 | -3.31% | $2.90B | vs ACAD |
| TLXTelix Pharmaceuticals Limited ADR | 8.37 | -3.90% | $2.84B | vs ACAD |
| BHCBausch Health Companies Inc. | 8.22 | -3.97% | $3.08B | vs ACAD |
| XERSXeris Biopharma Holdings Inc. | 16.97 | +2.11% | $3.10B | vs ACAD |
| SLSSELLAS Life Sciences Group Inc. | 13.66 | -8.08% | $2.78B | vs ACAD |
| VKTXViking Therapeutics Inc. | 24.77 | -4.14% | $3.16B | vs ACAD |
| ABCLAbCellera Biologics Inc. | 9.69 | -7.45% | $3.16B | vs ACAD |
Indexes, lists and sector
ACADIA Pharmaceuticals stock FAQ
What is ACADIA Pharmaceuticals's stock price today?
ACAD last traded at $17.11 as of Nov 20, 4:00 PM EST, down 2.73% on the day. Prices are delayed at least 15 minutes.
What is ACAD's P/E ratio?
ACAD trades at a trailing P/E ratio of 8.07 and a forward P/E of 15.75.
Who is ACADIA Pharmaceuticals's CEO?
Ms. Catherine E. Owen Adams is the chief executive officer of ACADIA Pharmaceuticals Inc., which has about 796 employees.
What is the ACAD 52-week high?
The 52-week high for ACAD is $30.96 and the 52-week low is $15.86. The stock is currently 44.7% below its high.